Magnesium and Metabolic Syndrome
Objective : to test the BP lowering-effect of oral magnesium supplementation, as magnesium chloride (MgCl2) solution, 2.5 g daily, in uncomplicated hypertensive type 2 diabetic subjects with decreased serum magnesium levels Design : Randomised double blind placebo controlled trial. Setting : Outpatients with type 2 diabetes from Durango, city in northern Mexico Subjects : 82 subjects between 40 and 75 years of age with type 2 diabetes serum magnesium deficiency and uncomplicated hypertension.
Interventions : During 4 months the intervention group received 2.5 gr of magnesium chloride (50 ml of a solution containing 50 gr of MgCl2 by 1000 ml of solution ). Controls received inert placebo.
Main outcome measure: Change in blood pressure. Increase of serum magnesium Secondary outcomes measures: Changes in lipid profile
|Diabetes Mellitus High Blood Pressure Hypomagnesemia||Dietary Supplement: Magnesium chloride Other: Placebo||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
|Official Title:||Hypomagnesemia as a Risk Factor for Development of Metabolic Syndrome|
- Reduction in the systolic and diastolic blood pressures [ Time Frame: 2 y ]
- Average increase of serum magnesium levels Changes in lipid profile [ Time Frame: 2 y ]
|Study Start Date:||July 2006|
|Study Completion Date:||November 2007|
|Primary Completion Date:||August 2007 (Final data collection date for primary outcome measure)|
Active Comparator: 1
Dietary Supplement: Magnesium chloride
Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
Placebo Comparator: 2
Subjects in the control group received inert placebo once per day during 4 months
Please refer to this study by its ClinicalTrials.gov identifier: NCT00603499
|Biomedical Research Unit|
|Durango, Mexico, 34067|
|Principal Investigator:||Martha Rodriguez-Moran, MD, MSc, PhD||Instituto Mexicano del Seguro Social|